Other highlights in the October 1 issue of JNCI

September 30, 2003

Study Finds No Improvement in Lung Cancer Survival After Adjuvant Chemotherapy

Adjuvant chemotherapy has been proposed as a way to improve the poor survival rates of patients with surgically removed non-small-cell lung cancer (NSCLC). However, a new study has found no such benefit associated with adjuvant chemotherapy in these patients. Giorgio V. Scagliotti, M.D., Ph.D., of the University of Torino, Italy, and colleagues compared outcomes of patients with completely resected stage I, II, or IIIA NSCLC who were randomly assigned to receive either adjuvant chemotherapy or no treatment after surgery. The chemotherapy regimen consisted of mitomycin C, vindesine, and cisplatin every three weeks for three cycles. After 5 years of follow-up, overall and progression-free survival were similar in the treated and untreated groups. The authors report poor compliance with the chemotherapy regimen used in this study due to toxicity. "Future studies should explore more effective treatments," they conclude.

Selenium Ineffective for Preventing Secondary Skin Cancers, Study Shows

Among individuals at high risk for nonmelanoma skin cancer, selenium supplementation does not appear to prevent basal cell carcinomas and may increase the risk of squamous cell carcinoma and total nonmelanoma skin cancer, according to results from the Nutritional Prevention of Cancer Trial. Anna J. Duffield-Lillico, Ph.D., of the Memorial Sloan-Kettering Cancer Center in New York, James R. Marshall, Ph.D., of the Roswell Park Cancer Institute, and colleagues examined the risk of nonmelanoma skin cancer among 1,312 patients who had previously had the disease. The patients were randomly assigned to receive 200 micrograms of selenium per day or a placebo. At the end of the study, there was no association between selenium supplementation and risk of basal cell carcinoma. However, selenium supplementation was associated with an increased risk of squamous cell carcinoma and of total nonmelanoma skin cancer.

Contact: Deborah Pettibone, Roswell Park Cancer Institute, 716-845-8593;
fax: 716-845-8362, deborah.pettibone@roswellpark.org.

Titles of additional articles appearing in the October 1 JNCI:
Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.